Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months
In the last three months, this biotech stock outperformed Nvidia (NVDA) by over 3x.
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist.
In the last three months, this biotech stock outperformed Nvidia (NVDA) by over 3x.
Three "strong buy" blue chips to consider in 2024.
A quick look at the biggest premarket moves today. NKE dips 11% while KRTX shoots up on a buyout deal.
Moderna's shares surged by more than 12% in premarket trading on Thursday following encouraging trial data for its skin cancer vaccine.
Which biotech stocks could gain even more on drug rollouts?
Recursion Pharmaceuticals, Schrodinger, and RadNet are some biotech companies that have used AI to outperform the market.
Priced low, penny stocks are the favorite of many investors who seek big percentages from fledgling incremental gains.
These biotech stocks mirror the resilience of tech stocks, and the current market provides significant potential.
New generation COVID treatments are underway, and the experts suggest you invest accordingly.